Dr. Grey AI

Goserelin (Zoladex)

Peptide

Goserelin is a synthetic decapeptide GnRH agonist. FDA-approved in 1989, it is used for prostate cancer, breast cancer, and endometriosis. Clinical trials show 82% objective response in metastatic prostate cancer and 10-year survival rates of 42-87% depending on setting. Available as 3.6mg (monthly) and 10.8mg (3-month) subcutaneous implants.

Quick Answer

What it is

Goserelin is a synthetic decapeptide GnRH agonist. FDA-approved in 1989, it is used for prostate cancer, breast cancer, and endometriosis.

Key findings

  • Grade A: Testosterone Suppression (Prostate Cancer)
  • Grade A: PSA Suppression (Prostate Cancer)
  • Grade A: Overall Survival (Prostate) (Prostate Cancer)

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Goserelin (Zoladex)

Quick Facts: Goserelin (Zoladex)

  • Best Evidence:Grade A
  • Conditions Studied:2
  • Research Outcomes:11
  • Grade A Findings:6
  • Grade B Findings:2
  • Key Effect:Prostate Cancer
A6
B2
C3
D0
2 conditions · 11 outcomes

Detailed Outcomes

|
A
Testosterone Suppression
Achieves T ≤50 ng/dL in 1 month, ≤20 ng/dL in 3 months. Lower testosterone escape rates compared to some GnRH agonists.
large↓Improves
A
PSA Suppression
Maximum benefit in PSA suppression among GnRH agonists. 82% objective response rate in metastatic disease.
large↓Improves
A
Overall Survival (Prostate)
10-year OS 42.6-86% neoadjuvant, 87% adjuvant to prostatectomy, 49% absolute survival adjuvant to radiotherapy.
large↑Improves
A
Ovarian Function Suppression
Preferred option for OFS in premenopausal breast cancer. Established safety profile in clinical trials.
large↓Improves
A
Disease Control (Breast)
Effective for HR-positive breast cancer. Monthly and 3-monthly formulations show equivalent efficacy.
moderate↑Improves
A
Estrogen Suppression
Achieves effective estrogen suppression in premenopausal women for hormone receptor-positive breast cancer.
large↓Improves
B
Anti-Cancer Activity
57 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
moderate↑Improves
B
Safety/Tolerability
6 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
small↑Improves
C
Seizure Activity
3 preclinical studies support this finding. Primarily preclinical evidence.
small↓Improves
C
Mortality
3 human trials support this finding. Human clinical trial data available.
small↓Improves
C
Hormone Levels
3 human trials support this finding. Human clinical trial data available.
small↑Improves

Research Citations (41)

Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer.
(2024)
PMID: 38318809
Multicenter, prospective, single-arm clinical study to investigate the efficacy and safety of Zoladex (Goserelin acetate) 10.8 mg prior to surgery in Chinese premenopausal women with symptomatic uterine fibroids.
(2024)
PMID: 39624028
Clinical efficacy and safety of trimonthly administration of goserelin acetate 10.8 mg in premenopausal Chinese females with symptomatic adenomyosis: a prospective cohort study.
(2023)
PMID: 36563705
Erythema nodosum caused by goserelin acetate sustained-release: Case report and literature review.
(2023)
PMID: 37114900
Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety
(2022)
PMID: 35343198
Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.
(2022)
PMID: 35862873
Use of Goserelin for Ovarian Protection During Breast-Cancer Adjuvant Chemotherapy
(2018)
PMID: 28806126
Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer.
(2016)
PMID: 26350351
Spontaneous reports of seizure in association with leuprolide (lupron depot), goserelin (zoladex implant), and naferelin (synarel nasal spray).
(2013)
PMID: 23635751
Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer
(2012)
PMID: 22147428

Related Peptides

Triptorelin (Trelstar)

Peptide

2 shared conditions · 10 outcomes

Triptorelin is a synthetic decapeptide GnRH agonist. FDA-approved in 2000, available as 1-month (3.75mg), 3-month (11.25mg), and 6-month (22.5mg) formulations. Clinical trials show 97.5% achieve castrate testosterone by day 29 with 6-month formulation. 9-month survival significantly higher than leuprolide (97.0% vs 90.5%, p=0.033). Also approved for adjuvant breast cancer treatment.